ライフサイエンスコーパス: vesicular stomatitis

1 mented the antiviral effects of IFN1 against vesicular stomatitis and hepatitis C viruses in human ce

2 ainst Ebola and Lassa fever VLPs, as well as vesicular stomatitis and rabies viruses (VSV and RABV, r

3 including influenza A, Zika, Ebola, Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not muri

4 of vesiculovirus-based therapies.IMPORTANCE Vesicular stomatitis Indiana virus (VSIV) is a veterinar

5 Vesicular stomatitis Indiana virus (VSIV), formerly know

6 se surrogate systems such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses o

7 hanced ISG expression and protection against vesicular stomatitis Indiana virus infection compared wi

8 We studied the cytotoxic activity of a vesicular stomatitis/measles hybrid virus (VSV-FH), whic

9 oma cells to infection by Lassa, measles and vesicular stomatitis pseudoviruses.

10 IDLVs pseudotyped with different envelopes (vesicular stomatitis, Rabies, Mokola and Ross River vira

11 with transient detection of the recombinant vesicular stomatitis vaccine virus in blood.

12 EPNs that incorporate the vesicular stomatitis viral glycoprotein can fuse with ta

13 rms, methyltransferase-defective recombinant vesicular stomatitis virus (mtdVSV) and a DNA vaccine.

14 The recombinant vesicular stomatitis virus (rVSV) Ebola vaccine was show

15 Recently, we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV c

16 ough not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovir

17 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing

18 onstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has sti

19 ion of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing fil

20 Recombinant vesicular stomatitis virus (rVSV) was shown to be a high

21 icacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccin

22 tenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidat

23 The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

24 approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

25 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors,

26 immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make th

27 EBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surf

28 Vesicular stomatitis virus (VSV) (a rhabdovirus) and its

29 een shown to induce G(2)/M arrest.IMPORTANCE Vesicular stomatitis virus (VSV) (a rhabdovirus) and its

30 ), only HuMxA is considered antiviral toward vesicular stomatitis virus (VSV) (a rhabdovirus).

31 t on the replication of the (-)ssRNA viruses vesicular stomatitis virus (VSV) (Rhabdoviridae family)

32 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic duct

33 at intermediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (C

34 n of herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) and impaired the replic

35 ve immune functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriom

36 The L proteins of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus (RABV)

37 nctional L protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catal

38 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdovirus

39 d infections with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncyti

40 that two RNA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV

41 h available experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus

42 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as

43 ers, which have been employed here to purify vesicular stomatitis virus (VSV) as a model case, howeve

44 y show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-

45 Using vesicular stomatitis virus (VSV) as a model, we coinfect

46 e, we describe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeri

47 re we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) assemble to include CD4

48 Vesicular stomatitis virus (VSV) assembly requires conde

49 Vesicular stomatitis virus (VSV) based oncolytic viruses

50 we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2

51 g ligands can be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glyc

52 on content release and infection by chimeric vesicular stomatitis virus (VSV) containing the envelope

53 Recombinant vesicular stomatitis virus (VSV) encoding the hemaggluti

54 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F a

55 ion of ACT with systemic administration of a vesicular stomatitis virus (VSV) engineered to express t

56 Vesicular stomatitis virus (VSV) exhibits a remarkably r

57 iously, we developed a replication-competent vesicular stomatitis virus (VSV) expressing a modified f

58 Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a ma

59 of neurotropism, we asked whether a chimeric vesicular stomatitis virus (VSV) expressing the EBOV gly

60 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zai

61 mental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire C

62 usly demonstrated that recombinant wild-type vesicular stomatitis virus (VSV) expressing the HBV midd

63 oV HKU5 expressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) expressing the SARS-CoV

64 le retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G protein with dextran-

65 y(C) binding protein 2 (PCBP2) downregulates vesicular stomatitis virus (VSV) gene expression.

66 ll interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth.

67 Vesicular stomatitis virus (VSV) has been extensively st

68 Replication of vesicular stomatitis virus (VSV) has long served as a mo

69 ecause of its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a system

70 Vesicular stomatitis virus (VSV) has shown considerable

71 Vesicular stomatitis virus (VSV) has shown substantial p

72 ectious autonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprote

73 itis Indiana virus (VSIV), formerly known as vesicular stomatitis virus (VSV) Indiana (VSV(IND)), is

74 regions encompassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L prot

75 tion of Gp78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresp

76 Vesicular stomatitis virus (VSV) infection downregulates

77 impaired IFN production in macrophages after vesicular stomatitis virus (VSV) infection, and HIPK2-de

78 vely regulating the host IFN response during vesicular stomatitis virus (VSV) infection.

79 lso known as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

80 of BUD13-deficient macrophages to withstand vesicular stomatitis virus (VSV) infection.

81 Vesicular stomatitis virus (VSV) is a highly cytopathic

82 Vesicular stomatitis virus (VSV) is a promising oncolyti

83 Vesicular stomatitis virus (VSV) is a promising oncolyti

84 Recombinant vesicular stomatitis virus (VSV) is a promising therapeu

85 Vesicular stomatitis virus (VSV) is an archetypical memb

86 Vesicular stomatitis virus (VSV) is potent and a highly

87 Vesicular stomatitis virus (VSV) is the prototype for ne

88 polymerases since the first structure of the vesicular stomatitis virus (VSV) L protein determined in

89 electron cryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

90 The complex closely resembles the vesicular stomatitis virus (VSV) L-P, the one other know

91 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cy

92 The vesicular stomatitis virus (VSV) nucleoprotein (N) assoc

93 obial molecule against infection with either vesicular stomatitis virus (VSV) or influenza was demons

94 n direct cell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV

95 Vesicular stomatitis virus (VSV) P is dimeric with an ol

96 Assembly of vesicular stomatitis virus (VSV) particles requires the

97 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid

98 diated degree of shielding and the amount of vesicular stomatitis virus (VSV) particles.

99 yped HIV-1, murine leukemia virus (MLV), and vesicular stomatitis virus (VSV) particles.

100 entry, 49 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and tra

101 ent cell-to-cell fusion assays, and chimeric vesicular stomatitis virus (VSV) recombinants expressing

102 adult flies; loss of Toll-7 led to increased vesicular stomatitis virus (VSV) replication and mortali

103 function by RNAi inhibited an early stage of vesicular stomatitis virus (VSV) replication.

104 The vesicular stomatitis virus (VSV) RNA-dependent RNA polym

105 stimulated genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable prom

106 s (MoMLV) spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cel

107 In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its n

108 study, we developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targe

109 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore

110 with miRNA inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that

111 an immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutrali

112 resses cytosolic poly(I:C), 5'ppp-dsRNA, and vesicular stomatitis virus (VSV) triggers IFN-I expressi

113 didate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that la

114 nfluenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and

115 Vesicular stomatitis virus (VSV) vectors that express he

116 rements in a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped wit

117 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its

118 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of

119 e, three papers describe the pseudotyping of vesicular stomatitis virus (VSV) with the SARS-CoV-2 spi

120 the antiviral activity of interferon against vesicular stomatitis virus (VSV), a model virus that who

121 Vesicular stomatitis virus (VSV), a negative-sense RNA v

122 Work with vesicular stomatitis virus (VSV), a prototype, supports

123 aviviridae, but has no appreciable effect on vesicular stomatitis virus (VSV), a rhabdovirus.

124 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer

125 K-deficient MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STIN

126 ks with DNA, modified vaccinia Ankara (MVA), vesicular stomatitis virus (VSV), adenovirus type 5 (Ad5

127 ly used to pseudotype glycoprotein-deficient vesicular stomatitis virus (VSV), allowing studies of BA

128 this observation, we engineered a strain of vesicular stomatitis virus (VSV), an oncolytic rhabdovir

129 activity of these ISGs against an RNA virus, vesicular stomatitis virus (VSV), and a DNA virus, murin

130 ycoproteins of Ebola virus, influenza virus, vesicular stomatitis virus (VSV), and measles virus in G

131 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothe

132 n immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replicati

133 infection limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis v

134 ombinant rabies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the

135 binant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type o

136 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rab

137 Within 2-6 hours after infection by vesicular stomatitis virus (VSV), newly assembled VSV pa

138 al infection with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

139 y, PGAM5 deficient MEFs, upon infection with vesicular stomatitis virus (VSV), revealed diminished IF

140 ted DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to protect it from nAb

141 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three

142 RdRP with those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that bo

143 cell lines and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA comple

144 prototype of NNS RNA virus gene expression, vesicular stomatitis virus (VSV), we determined the impo

145 By studying vesicular stomatitis virus (VSV), we identify the large

146 Working with vesicular stomatitis virus (VSV), we previously showed t

147 reporter strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinje

148 pplication of a novel viral tracer, based on vesicular stomatitis virus (VSV), which directs retrogra

149 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses

150 us (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was

151 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine

152 binants carrying large transgenes.IMPORTANCE Vesicular stomatitis virus (VSV)-based oncolytic viruses

153 To address these limitations, we devised a vesicular stomatitis virus (VSV)-based probe to display

154 Using a vesicular stomatitis virus (VSV)-based pseudoparticle se

155 Here, vesicular stomatitis virus (VSV)-based pseudovirions dis

156 antibody repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 mill

157 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVS

158 In the vesicular stomatitis virus (VSV)-induced encephalitis mo

159 In vesicular stomatitis virus (VSV)-infected Huh7 cells, th

160 -like helicase (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of

161 ue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta

162 ve and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

163 h influenza virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

164 ll carcinoma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

165 mouse model of prostate cancer infected with vesicular stomatitis virus (VSV).

166 t cell targets for the matrix (M) protein of vesicular stomatitis virus (VSV).

167 NS RNA viruses comes largely from studies of vesicular stomatitis virus (VSV).

168 r pattern was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

169 al infection by the neurotropic rhabdovirus, vesicular stomatitis virus (VSV).

170 and it inhibits the replication of HSV-1 and vesicular stomatitis virus (VSV).

171 ferent turns, as is observed for the related Vesicular stomatitis virus (VSV).

172 s virus (LCMV); influenza A virus (IAV); and vesicular stomatitis virus (VSV).

173 ite-directed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA vi

174 hanisms by which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initi

175 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovir

176 se in early endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fu

177 Vesicular stomatitis virus and influenza A virus infecti

178 een after infection of IL-21R(-/-) mice with vesicular stomatitis virus and influenza virus.

179 n response to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to trans

180 ved from viral infections with influenza and vesicular stomatitis virus can persist after resolution

181 al RNA-dependent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-

182 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sol

183 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona v

184 nuclear cells were infected with recombinant vesicular stomatitis virus encoding EBOV antigens.

185 pressing influenza, measles, Ebola, Lassa or vesicular stomatitis virus envelope glycoproteins enable

186 mal human glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon

187 tion activity in vitro against a recombinant vesicular stomatitis virus expressing MACV GPC (VSV-MACV

188 in lungs following intranasal infection with vesicular stomatitis virus expressing OVA and influenza

189 ne of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprot

190 ression plasmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavir

191 these MAbs to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavir

192 remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses

193 transfected secretory membrane glycoprotein, vesicular stomatitis virus G (VSVG) glycoprotein, was re

194 While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) effici

195 pon infection of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudo

196 F) but, surprisingly, not the trafficking of vesicular stomatitis virus G protein (VSV-G) to the cell

197 "Gectosomes," are designed to co-encapsulate vesicular stomatitis virus G protein (VSV-G) with bioact

198 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of inter

199 ination with virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promote

200 gradation of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors in

201 hen an alphavirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the o

202 Forest virus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been

203 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudoty

204 hy, we found that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased

205 g human GBA to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demon

206 related class III fusion proteins, including vesicular stomatitis virus glycoprotein G (VSV-G) or bac

207 -1 envelope (Env) glycoprotein, but not with vesicular stomatitis virus glycoprotein G (VSV-G).

208 uction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with m

209 stricted to retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

210 Vesicular stomatitis virus has been shown to bud basolat

211 tent antiviral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN rece

212 o-localization with RIG-I and with infecting vesicular stomatitis virus in Cos-7 cells.

213 In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vect

214 wth inhibition, prolonged protection against vesicular stomatitis virus infection and enhanced transc

215 defect early after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cyto

216 uster activates the IFN pathway and inhibits vesicular stomatitis virus infection by directly targeti

217 e switched Ig in response to immunization or vesicular stomatitis virus infection is strongly impaire

218 ce in lymphocytic choriomeningitis virus and vesicular stomatitis virus infection models.

219 with apoptotic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble in

220 osynthetic inhibition during influenza A and vesicular stomatitis virus infection, but not murine hep

221 Using an intranasal vesicular stomatitis virus infection, we demonstrated th

222 ation and to induce apoptosis in response to vesicular stomatitis virus infection.

223 xpression for EmGFP/IL-15 upregulation after vesicular stomatitis virus infection.

224 inhibition also occurred in the presence of vesicular stomatitis virus M (matrix) protein, another v

225 es a rational approach to the attenuation of vesicular stomatitis virus neurovirulence.

226 action results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola

227 Among vaccines, only the vesicular stomatitis virus platform has been successful

228 and no impact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus

229 V virus-like particle, and EBOV glycoprotein/vesicular stomatitis virus pseudovirion.

230 Using vesicular stomatitis virus pseudovirions bearing EBOV gl

231 ion conferred by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack nativ

232 esis and shows reduced capability to control vesicular stomatitis virus replication and to induce apo

233 by IFN in both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

234 d-induced interferon production and enhanced vesicular stomatitis virus replication.

235 ession of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-ce

236 proteins from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synt

237 lescents and 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

238 By in situ analyses of vesicular stomatitis virus RNA synthesis, specific activ

239 We have used a collection of vesicular stomatitis virus strains that had been evolvin

240 RS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G

241 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in L

242 otective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A

243 A replication-competent vesicular stomatitis virus vaccine expressing the Ebola

244 cell lines to infection by the nonretrovirus vesicular stomatitis virus were indistinguishable.

245 rabies virus) and heterologous (inactivated vesicular stomatitis virus) antigens and acceptable accu

246 whereas other RNA viruses (Sindbis virus and vesicular stomatitis virus) are not.

247 sed by two TLR3-dependent viruses (HSV-1 and vesicular stomatitis virus) were high in fibroblasts fro

248 constructs involving viral vectors (such as vesicular stomatitis virus), and antisense compounds dir

249 In this article, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruse

250 Vesicular stomatitis virus, a single-stranded RNA virus,

251 d vaccinia virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, a

252 ruses, including encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susc

253 gion I) of the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

254 by arboviruses, including Sindbis virus and vesicular stomatitis virus, but this innate restriction

255 d RNA virus, including influenza A virus and vesicular stomatitis virus, by a mechanism independent o

256 measles virus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus

257 vity of alpha interferon (IFN-alpha) against vesicular stomatitis virus, Indiana serotype (VSV(IND)),

258 ction as an entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis

259 tu formation of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A v

260 dary challenges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispe

261 sponses than UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

262 neurotropic viruses, including rabies virus, vesicular stomatitis virus, Semliki Forest virus, and he

263 Remarkably, infection with vesicular stomatitis virus, vaccinia virus, and a variet

264 starting with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion

265 EBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expre

266 laque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expre

267 used a vesicular stomatitis virus-based probe to isolate B cell

268 A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a su

269 observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZE

270 A live, recombinant vesicular stomatitis virus-based vaccine has been deploy

271 ADAM15 expression enhanced rhinovirus 16 and vesicular stomatitis virus-mediated proinflammatory cyto

272 on virus entry or coreceptor expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication

273 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-Z

274 The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly

275 for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV

276 Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV

277 2503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

278 , lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

279 safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

280 for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine (rV

281 uencing backed up the use of the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine in

282 is observed after intranasal challenge with vesicular stomatitis virus.

283 PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

284 a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

285 of H1N1, H6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

286 reovirus, HIV-1, human metapneumovirus, and vesicular stomatitis virus.

287 ecting mice from neuropathogenesis caused by vesicular stomatitis virus.

288 ring infection by Listeria monocytogenes and vesicular stomatitis virus.

289 otection from death after CNS infection with vesicular stomatitis virus.

290 vels of RIG-I and resistance to infection by vesicular stomatitis virus.

291 the pseudotypes bearing the glycoprotein of vesicular stomatitis virus.

292 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high

293 Recombinant vesicular stomatitis viruses (rVSV) expressing foreign g

294 Here we test replication-competent vesicular stomatitis viruses (VSV) on 19 primary human m

295 RhIVs are based on vesicular stomatitis viruses (VSV), but viral entry is m

296 eins via replication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenovirus

297 We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatme

298 Chimeric vesicular stomatitis viruses with the EBOV glycoprotein

299 d infectivity assays with BCoV-S-pseudotyped vesicular stomatitis viruses.

300 uenza A (IAV), measles (MV), Sendai (SV), or vesicular stomatitis (VSV) virus.